繁體
简体
US STOCKS
FUNDS
FX & CRYPTO
SH/SZ-HK
HK STOCKS
Sign Up
Login
Home
Fund Quote
Funds
Fund Quote
Fund Quote
Fund Chart
Facts & Fees
Fund Descriptions
Comparison with similar fund
Fund News
Funds
Fund News
Latest Fund News
Commentary
Funds
Commentary
Fund Commentary
Tools
Funds
Tools
Predefined Funds Screener
Fund Search
Fund Comparison
Menu
Funds
Menu
Home
Feedback
Fund Quote
Fund Quote
Fund Chart
Facts & Fees
Fund Descriptions
Comparison with similar fund
Fund News
Latest Fund News
Commentary
Fund Commentary
Tools
Predefined Funds Screener
Fund Search
Fund Comparison
Latest Fund News
News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.
*Mandatory Fields
Receiver
*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address
*
Content Sharing
CN Domestic Innovative Drugs Approved since 14th FYP Hit RMB100B in Mkt Size
The 2024 China Pharmaceutical Industry Development Conference and the International Biopharmaceutical Industry Week Shanghai 2024 were held in Shanghai on 16 November, reported Xin...
Reset
Send
The window will close in 5 seconds
CN Domestic Innovative Drugs Approved since 14th FYP Hit RMB100B in Mkt Size
Back
Share
Print
Font Size
T
T
Related Fund News >>
HK Latest Unemployment Rate Edges Up to 3.1%, Narrowly Higher than Estimate
CN Oct Jobless Rate of Teenagers Ebbs to 17.1%
G Sachs Predicts Central Banks' Demand, Fed Rate Cuts to Drive Gold Prices to US$3K in 2025
The 2024 China Pharmaceutical Industry Development Conference and the International Biopharmaceutical Industry Week Shanghai 2024 were held in Shanghai on 16 November, reported Xinhua News Agency.
Since the 14th Five-Year Plan (FYP), the quantity and quality of domestic innovative drugs in mainland China have ascended in tandem, with a total of 113 domestic innovative drugs approved for marketing, which is 2.8 times the number of new drugs approved in the 13th FYP, with the market scale of RMB100 billion, based on the data released at the conference.
Since the 14th FYP, the mainland China has accelerated innovation and breakthroughs in high-end medical devices. 165 innovative medical devices developed by Chinese enterprises have been approved for marketing, and the products incorporate cutting-edge technologies such as deep learning, magnetic levitation and additive manufacturing.
~
AAStocks Financial News
Web Site: www.aastocks.com
News Provided by AASTOCKS
Most Popular News
Inflation Rate YoY in India for Mar is 4.85%, Below Forecast
CAICT: CN Jul Handset Shipments Climb 30.5% YoY; 5G Handsets Up 37.2%
HK Latest Unemployment Rate Edges Up to 3.1%, Narrowly Higher than Estimate
<Asia>Nikkei Rebounds 2,957 pts/ 9.4% at Midday as USD/ JPY Ebbs 0.9%; Banks Narrow Gains
CN Jun Logistics Prosperity Index Falls to 51.6, Remains in Expansion Range
HKMA: Total Assets of Exchange Fund $4.1339T at End-Sep, Up $152.4B MoM
Saudi's First ETF Tracking HK Shrs Listed with Size of US$1.2B+
Unemployment Rate in Japan for Sep is 2.4%, Below Forecast
Building Permits Prel in United States for Sep is 1.428M, Below Forecast
Unemployment Rate in Italy for Jan is 7.2%, Meets Expectations
SITEMAP
AASTOCKS.com
- FUNDS Mainpage
Fund Quote
- Fund Quote
- Fund Chart
- Facts & Fees
- Fund Descriptions
- Comparison with similar fund
Fund News
- Latest Fund News
Commentary
- Fund Commentary
Tools
- Predefined Funds Screener
- Fund Search
- Fund Comparison
Fund Type:
【Alternative Investment】
【Balanced Funds】
【Equity Funds】
【Fixed Income Funds】
【Money Market Funds】
【Australia Funds】
【Brazil Funds】
【China A Share Funds】
【Energy Funds】
【Gold & Precious Metal Funds】
【High Dividend Funds】
【BRIC Funds】
【ASEAN Funds】
【China Funds】
Fund Information:
【Unit Trusts】【Mutual Funds】【Hedge funds】【Balanced Mutual Funds】【Fund】【Mutual Fund】【Fund Trading】【Fund House】【Fund company】【Buy Fund】
【Sell Fund】【Fund Investment】【Mutual Fund Center】【ETF】【Bond Funds】【What is mutual fund】【Financial Planning】【Funds Portfolio】【Fund Management】
【Fund Manager】【Emerging Markets Funds】【Index Funds】【Funds Performance】【Funds Return】【Funds data】【Funds Ranking】【Hong Kong Funds】
【Stocks Funds 】【Funds News】【Funds Quote】【Best Fund】
About US
|
Register
|
Advertisements
|
Help
|
Disclaimer
|
Privacy Policy
|
Contact Us
|
Careers
Email
support@aastocks.com
AASTOCKS.COM LIMITED (阿斯達克網絡信息有限公司) All rights reserved.
This fund quoted price is compiled by AASTOCKS from the individual fund management company's public information material, and meant for information only. Whilst all attempts have been made by AASTOCKS to present the information accurately and completely, AASTOCKS does not guarantee its accuracy or reliability and accepts no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions. Readers are advised to read the prospectus before making any investment decision. It is important to read our disclaimers carefully.
The above is strictly for information purposes only and should not be considered an offer, or solicitation, to deal in any of the mentioned funds. Investment involves risk, emerging markets may have greater risk than developed markets. Subscriptions may only be made on the basis of the relevant offering documents, most recent annual financial statement and semi-annual financial statements if published thereafter. The value of investments and the income received from them (if any) may be volatile and could change substantially within a short period of time. Past performance is not a guide to future performance. The investment returns are denominated in the base currency of the fund. US dollar / HK dollar based investors are therefore exposed to fluctuations in the US dollar / HK dollar / base currency exchange rate.
BEFORE MAKING AN INVESTMENT, YOU SHOULD REFER TO THE RELEVANT OFFERING DOCUMENTS AND IN PARTICULAR TO THE INVESTMENT POLICIES AND THE RISK FACTORS. YOU SHOULD ENSURE THAT YOU FULLY UNDERSTAND THE RISKS ASSOCIATED WITH THE FUND AND SHOULD ALSO CONSIDER YOUR OWN INVESTMENT OBJECTIVE AND RISK TOLERANCE LEVEL. YOU ARE REMINDED THAT YOU ARE RESPONSIBLE FOR YOUR INVESTMENT DECISION AND SHOULD NOT INVEST UNLESS THE INTERMEDIARY WHO OFFERS OR SELLS THE FUND TO YOU HAS ADVISED THAT THE FUND IS SUITABLE FOR YOU AND HAS EXPLAINED WHY, INCLUDING HOW BUYING THE FUND WOULD BE CONSISTENT WITH YOUR INVESTMENT OBJECTIVE. IF IN DOUBT, PLEASE SEEK INDEPENDENT FINANCIAL AND PROFESSIONAL ADVICE.
The information and products contained within this website are restricted to investors within Hong Kong. There are important legal and regulatory restrictions which apply to this website. These are laid out in the
Disclaimer section
which you are advised to read before proceeding. By proceeding, you are representing that you have understood and accepted the restrictions set out in the Disclaimer section.
Third party websites provided by hyperlinks on this website are completely beyond the control of AASTOCKS. Accordingly, AASTOCKS accepts no responsibility for the accuracy, completeness and legality of the contents of such third party website, or for any offers, services and products contained therein.
By visiting this website, you are representing that you have understood and accepted the content set out in the
Disclaimer of AASTOCKS
.